JP2017533727A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533727A5 JP2017533727A5 JP2017538570A JP2017538570A JP2017533727A5 JP 2017533727 A5 JP2017533727 A5 JP 2017533727A5 JP 2017538570 A JP2017538570 A JP 2017538570A JP 2017538570 A JP2017538570 A JP 2017538570A JP 2017533727 A5 JP2017533727 A5 JP 2017533727A5
- Authority
- JP
- Japan
- Prior art keywords
- biomarker
- compound
- level
- antibody
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 31
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 7
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 3
- 239000000090 biomarker Substances 0.000 claims 37
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 239000000523 sample Substances 0.000 claims 10
- 239000013078 crystal Substances 0.000 claims 6
- 239000013074 reference sample Substances 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 102100021069 E3 ubiquitin-protein ligase ZFP91 Human genes 0.000 claims 3
- 102100021467 Histone acetyltransferase type B catalytic subunit Human genes 0.000 claims 3
- 101000818429 Homo sapiens E3 ubiquitin-protein ligase ZFP91 Proteins 0.000 claims 3
- 101000898976 Homo sapiens Histone acetyltransferase type B catalytic subunit Proteins 0.000 claims 3
- 101000614821 Homo sapiens Kynurenine-oxoglutarate transaminase 1 Proteins 0.000 claims 3
- 101001132132 Homo sapiens Partner of Y14 and mago Proteins 0.000 claims 3
- 101000735463 Homo sapiens Protein mono-ADP-ribosyltransferase PARP4 Proteins 0.000 claims 3
- 101000788669 Homo sapiens Zinc finger MYM-type protein 2 Proteins 0.000 claims 3
- 102100021209 Kynurenine-oxoglutarate transaminase 1 Human genes 0.000 claims 3
- 102000008730 Nestin Human genes 0.000 claims 3
- 108010088225 Nestin Proteins 0.000 claims 3
- 102100034516 Partner of Y14 and mago Human genes 0.000 claims 3
- 102100034931 Protein mono-ADP-ribosyltransferase PARP4 Human genes 0.000 claims 3
- 102100025085 Zinc finger MYM-type protein 2 Human genes 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 210000005055 nestin Anatomy 0.000 claims 3
- 229940126062 Compound A Drugs 0.000 claims 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 2
- 102100038884 Major vault protein Human genes 0.000 claims 2
- 101710094960 Major vault protein Proteins 0.000 claims 2
- 101710159910 Movement protein Proteins 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 2
- 229960004942 lenalidomide Drugs 0.000 claims 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 2
- 229960000688 pomalidomide Drugs 0.000 claims 2
- 229960003433 thalidomide Drugs 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 125000001475 halogen functional group Chemical group 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- WENKGSGGXGQHSH-UHFFFAOYSA-N 3-(3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical class C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O WENKGSGGXGQHSH-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- MMJSZIMFGHOSBC-UHFFFAOYSA-N 2-methyl-5-nitro-3,1-benzoxazin-4-one Chemical compound C1=CC([N+]([O-])=O)=C2C(=O)OC(C)=NC2=C1 MMJSZIMFGHOSBC-UHFFFAOYSA-N 0.000 description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical group C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- FEQQEJUYIDIYPN-VIFPVBQESA-N (2s)-5-amino-2-[(7-nitro-3-oxo-1h-isoindol-2-yl)amino]-5-oxopentanoic acid Chemical compound O=C1N(N[C@@H](CCC(=O)N)C(O)=O)CC2=C1C=CC=C2[N+]([O-])=O FEQQEJUYIDIYPN-VIFPVBQESA-N 0.000 description 1
- SQCAKAAOLXAVQA-UHFFFAOYSA-N 1-aminopiperidine-2,6-dione;hydrochloride Chemical compound Cl.NN1C(=O)CCCC1=O SQCAKAAOLXAVQA-UHFFFAOYSA-N 0.000 description 1
- SCJORWDJJJWLJD-UHFFFAOYSA-N 2-(3-fluoro-2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1(F)CCC(=O)NC1=O SCJORWDJJJWLJD-UHFFFAOYSA-N 0.000 description 1
- GGKYLHNARFFORH-UHFFFAOYSA-N 2-amino-6-nitrobenzoic acid Chemical compound NC1=CC=CC([N+]([O-])=O)=C1C(O)=O GGKYLHNARFFORH-UHFFFAOYSA-N 0.000 description 1
- KHEXQYOPAOPUQQ-UHFFFAOYSA-N 3-(2-methyl-5-nitro-4-oxoquinazolin-3-yl)piperidine-2,6-dione Chemical compound CC1=NC2=CC=CC([N+]([O-])=O)=C2C(=O)N1C1CCC(=O)NC1=O KHEXQYOPAOPUQQ-UHFFFAOYSA-N 0.000 description 1
- XEROJSNWACQJEM-UHFFFAOYSA-N 3-(7-amino-3-oxo-1h-isoindol-2-yl)-3-fluoro-5-hydroxypiperidine-2,6-dione Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1(F)CC(O)C(=O)NC1=O XEROJSNWACQJEM-UHFFFAOYSA-N 0.000 description 1
- QNHYEPANFMRYAK-UHFFFAOYSA-N 3-fluoro-3-(3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical compound C1C2=CC=CC=C2C(=O)N1C1(F)CCC(=O)NC1=O QNHYEPANFMRYAK-UHFFFAOYSA-N 0.000 description 1
- JVYMXRZSOURPSE-UHFFFAOYSA-N 5-amino-4-(4-amino-1,3-dioxoisoindol-2-yl)-5-oxopentanoic acid Chemical compound C1=CC(N)=C2C(=O)N(C(CCC(O)=O)C(=O)N)C(=O)C2=C1 JVYMXRZSOURPSE-UHFFFAOYSA-N 0.000 description 1
- FPNJYPLJTAYAMP-UHFFFAOYSA-N 7a-(2,6-dioxopiperidin-3-yl)-3ah-isoindole-1,3-dione Chemical class C1=CC=CC2C(=O)NC(=O)C21C1CCC(=O)NC1=O FPNJYPLJTAYAMP-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 150000003950 cyclic amides Chemical class 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical group C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000003011 styrenyl group Chemical class [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462063343P | 2014-10-13 | 2014-10-13 | |
| US62/063,343 | 2014-10-13 | ||
| US201462085127P | 2014-11-26 | 2014-11-26 | |
| US62/085,127 | 2014-11-26 | ||
| PCT/US2014/068802 WO2016060702A1 (en) | 2014-10-13 | 2014-12-05 | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017533727A JP2017533727A (ja) | 2017-11-16 |
| JP2017533727A5 true JP2017533727A5 (enExample) | 2018-01-25 |
Family
ID=55747078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017538570A Pending JP2017533727A (ja) | 2014-10-13 | 2014-12-05 | 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20170242014A1 (enExample) |
| EP (1) | EP3207151A4 (enExample) |
| JP (1) | JP2017533727A (enExample) |
| WO (1) | WO2016060702A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS52349B (sr) | 2006-09-26 | 2012-12-31 | Celgene Corporation | 5-supstituisani derivati hinazolinona kao antitumorski agensi |
| LT3202460T (lt) | 2010-02-11 | 2019-10-10 | Celgene Corporation | Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus |
| CA2829570C (en) | 2011-03-11 | 2019-05-07 | Celgene Corporation | Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
| EP2892887B1 (en) | 2012-09-04 | 2020-07-15 | Celgene Corporation | Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof |
| WO2014116573A1 (en) | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| CA2932120C (en) | 2013-12-06 | 2023-09-19 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| JP6585737B2 (ja) | 2015-06-02 | 2019-10-02 | セルジーン コーポレイション | セレブロン関連タンパク質の比を使用してがんの治療のための薬物の有効性を決定するための方法 |
| JP2018529344A (ja) | 2015-09-25 | 2018-10-11 | セルジーン コーポレイション | びまん性大細胞型ｂ細胞リンパ腫の治療方法及び薬物に対する応答性の予測因子としてのバイオマーカー利用 |
| MX390772B (es) | 2016-01-08 | 2025-03-21 | Celgene Corp | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. |
| WO2018010142A1 (en) * | 2016-07-14 | 2018-01-18 | Shanghai Meton Pharmaceutical Co., Ltd | Iso-citrate dehydrogenase (idh) inhibitor |
| US10969381B2 (en) * | 2018-05-23 | 2021-04-06 | Celgene Corporation | Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile |
| KR102429562B1 (ko) | 2019-03-22 | 2022-08-05 | 재단법인 아산사회복지재단 | 간세포암 진단용 바이오마커 세레브론 및 이에 특이적인 신규한 단일클론항체 |
| US20250011879A1 (en) * | 2021-12-02 | 2025-01-09 | Ohio State Innovation Foundation | Methods and compositions related to inflammatory gene panel |
| KR20250016230A (ko) * | 2022-05-27 | 2025-02-03 | 브리스톨-마이어스 스큅 컴퍼니 | 만성 피로 증후군 및 롱 covid에 대한 바이오마커 및 이의 용도 |
| CN115078722A (zh) * | 2022-06-08 | 2022-09-20 | 北京化工大学 | 一种筛选鉴定肝细胞癌的方法及其应用 |
| CN115407068B (zh) * | 2022-09-20 | 2024-07-12 | 华中科技大学同济医学院附属协和医院 | Oma1蛋白作为胶质瘤标记物的应用及其试剂盒 |
| CN119709998B (zh) * | 2024-11-28 | 2025-10-10 | 北京大学深圳医院（北京大学深圳临床医学院） | 检测circATP2B4的试剂在制备用于诊断口腔鳞状细胞癌的产品中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070099209A1 (en) * | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2007084992A2 (en) * | 2006-01-19 | 2007-07-26 | The University Of Chicago | Prognosis and therapy predictive markers and methods of use |
| US20100284915A1 (en) * | 2006-06-30 | 2010-11-11 | Hongyue Dai | Genes associated with chemotherapy response and uses thereof |
| MX2009002936A (es) * | 2006-09-19 | 2009-04-01 | Novartis Ag | Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf. |
| CN103688176A (zh) * | 2011-04-29 | 2014-03-26 | 细胞基因公司 | 利用cereblon作为预报因子治疗癌和炎性疾病的方法 |
| EP2944961A1 (en) * | 2011-05-06 | 2015-11-18 | XenTech | Markers for cancer prognosis and therapy and methods of use |
| JP2015504677A (ja) * | 2012-01-13 | 2015-02-16 | セルジーン コーポレイション | 肝細胞癌治療のためのバイオマーカー |
| CA3136093C (en) * | 2012-06-29 | 2025-07-08 | Celgene Corporation | METHODS FOR DETERMINING THE EFFICACY OF A DRUG USING PROTEINS ASSOCIATED WITH CEREBLON |
-
2014
- 2014-12-05 JP JP2017538570A patent/JP2017533727A/ja active Pending
- 2014-12-05 EP EP14904114.7A patent/EP3207151A4/en not_active Withdrawn
- 2014-12-05 WO PCT/US2014/068802 patent/WO2016060702A1/en not_active Ceased
- 2014-12-05 US US15/518,472 patent/US20170242014A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533727A5 (enExample) | ||
| JP2023109922A (ja) | 癌を治療する方法 | |
| ES2676734T3 (es) | Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas | |
| ES2518919T3 (es) | Derivados del ácido 4-(Indol-7-ilcarbonilaminometil)ciclohexanocarboxílico como antagonistas del receptor EP4 útiles para el tratamiento de la insuficiencia renal crónica o la nefropatía diabética | |
| JP5544170B2 (ja) | 新規インドール誘導化合物およびそれを含有する薬剤組成物 | |
| JP6648115B2 (ja) | 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジン−２（１ｈ）−オンキノリノン誘導体 | |
| JP2020533277A5 (enExample) | ||
| TW200902503A (en) | New compounds | |
| TWI855993B (zh) | 作為vanin抑制劑之雜芳族化合物 | |
| AU2015304465B2 (en) | Salt of monocyclic pyridine derivative and crystal thereof | |
| MD3519398T2 (ro) | Compus de piridină | |
| JP2017528489A (ja) | 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのフェニルキノリノン誘導体 | |
| JP2017528491A (ja) | 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジニルキノリノン誘導体 | |
| JP2023541263A (ja) | ５－置換インドール３－アミド誘導体、その調製方法及び使用 | |
| BRPI0707689A2 (pt) | inibidores de polimerase viral | |
| WO2011140817A1 (zh) | 1-[（4-羟基哌啶-4-基）甲基]吡啶-2（1h）-酮衍生物及其制备方法和用途 | |
| WO2016052697A1 (ja) | 変異型イソクエン酸デヒドロゲナーゼ１阻害剤としてのイソキサゾール誘導体 | |
| Liao et al. | Design and optimization of novel 4-(2-fluorophenoxy) quinoline derivatives bearing a hydrazone moiety as c-Met kinase inhibitors | |
| WO2023147063A2 (en) | Compounds and methods for yap/tead modulation and indications therefor | |
| WO2006077851A1 (ja) | キノロン誘導体又はその塩 | |
| JP2024517473A (ja) | Ｙａｐ／ｔｅａｄの調節のための化合物及び方法ならびにそれらの適用 | |
| BR112020011602A2 (pt) | Forma cristalina e forma salina de um inibidor tgf-ssri e método de preparação dos mesmos | |
| JP6021148B2 (ja) | Ｌｓｔ−１及び／又はｌｓｔ−２によって輸送される化合物 | |
| TW201920136A (zh) | 作為組蛋白甲基轉移酶抑制劑的三環化合物 | |
| CN104945415B (zh) | 7H‑苯并异噁唑并[7,6‑e][1,3]噁嗪类衍生物及应用 |